DE2645466C2 - Verfahren zum Isolieren von Albumin aus Plasmaprodukten - Google Patents
Verfahren zum Isolieren von Albumin aus PlasmaproduktenInfo
- Publication number
- DE2645466C2 DE2645466C2 DE2645466A DE2645466A DE2645466C2 DE 2645466 C2 DE2645466 C2 DE 2645466C2 DE 2645466 A DE2645466 A DE 2645466A DE 2645466 A DE2645466 A DE 2645466A DE 2645466 C2 DE2645466 C2 DE 2645466C2
- Authority
- DE
- Germany
- Prior art keywords
- albumin
- separation
- ionic strength
- buffer
- exchanger
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000009027 Albumins Human genes 0.000 title claims description 57
- 108010088751 Albumins Proteins 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 41
- 238000000926 separation method Methods 0.000 claims description 25
- 150000001450 anions Chemical class 0.000 claims description 22
- 150000001768 cations Chemical class 0.000 claims description 20
- 239000012062 aqueous buffer Substances 0.000 claims description 12
- 238000005342 ion exchange Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- 239000000872 buffer Substances 0.000 description 25
- 150000002500 ions Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 229920005654 Sephadex Polymers 0.000 description 14
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 14
- 239000001632 sodium acetate Substances 0.000 description 14
- 235000017281 sodium acetate Nutrition 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 13
- 239000012507 Sephadex™ Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000013375 chromatographic separation Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 diethyl (2-hydroxypropyl) aminoethyl groups Chemical group 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 239000003058 plasma substitute Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000665 Cohn process Methods 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000018721 Macroglobulins Human genes 0.000 description 1
- 108010091934 Macroglobulins Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical group 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001612 separation test Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7511295A SE405549B (sv) | 1975-10-09 | 1975-10-09 | Forfarande for isolering av albumin ur plasmaprodukter genom kromatografisk fraktionering |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2645466A1 DE2645466A1 (de) | 1977-04-21 |
| DE2645466C2 true DE2645466C2 (de) | 1983-08-11 |
Family
ID=20325752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2645466A Expired DE2645466C2 (de) | 1975-10-09 | 1976-10-08 | Verfahren zum Isolieren von Albumin aus Plasmaprodukten |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4086222A (enrdf_load_stackoverflow) |
| JP (1) | JPS5247915A (enrdf_load_stackoverflow) |
| DE (1) | DE2645466C2 (enrdf_load_stackoverflow) |
| FR (1) | FR2327256A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1554592A (enrdf_load_stackoverflow) |
| SE (1) | SE405549B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2742150A1 (de) * | 1976-09-20 | 1978-03-23 | Monsanto Co | Verfahren zur herstellung von serumalbumin |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228154A (en) * | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
| DE3172210D1 (en) * | 1980-05-27 | 1985-10-17 | Miles Lab | Blood coagulation promoting product and process of preparing same |
| US4364861A (en) * | 1980-05-27 | 1982-12-21 | Cutter Laboratories, Inc. | Blood-coagulation-promoting products and methods of preparing them |
| FR2543448A1 (fr) * | 1983-04-01 | 1984-10-05 | Rhone Poulenc Spec Chim | Procede de fractionnement du plasma |
| FR2548670B1 (fr) * | 1983-07-07 | 1985-10-25 | Merieux Inst | Procede de preparation des principales proteines du sang hemolyse sous forme non denaturee |
| US4629705A (en) * | 1984-05-31 | 1986-12-16 | The Dow Chemical Company | Indirect-photometric chromatography done in and with a variable capacity weakly basic or acidic ion exchange column |
| DE3678003D1 (de) * | 1985-01-22 | 1991-04-18 | Ciba Geigy Ag | Anionisch modifizierte polysaccharide, verfahren zu deren herstellung und deren verwendung. |
| US4721572A (en) * | 1985-07-12 | 1988-01-26 | Miles Laboratories, Inc. | Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices |
| US4740306A (en) * | 1986-03-17 | 1988-04-26 | Temple University - Of The Commonwealth System Of Higher Education | Chromatographic column |
| JPS63102118U (enrdf_load_stackoverflow) * | 1986-12-23 | 1988-07-02 | ||
| NL8701915A (nl) * | 1987-08-14 | 1989-03-01 | Waander Riethorst | Adsorbensmateriaal en toepassing daarvan voor het isoleren van stollingsfaktoren. |
| IL88326A (en) * | 1987-11-18 | 1993-03-15 | Gist Brocades Nv | Purification of serum albumin |
| US4990447A (en) * | 1988-06-24 | 1991-02-05 | Gist-Brocades Nv | Process for the purification of serum albumin |
| JP3554796B2 (ja) * | 1988-10-31 | 2004-08-18 | 三菱ウェルファーマ株式会社 | アルブミン製剤及びその製造方法 |
| US5277818A (en) * | 1988-10-31 | 1994-01-11 | The Green Cross Corporation | Albumin preparation and process for preparing the same |
| FR2648048B1 (fr) * | 1989-06-08 | 1994-06-03 | Lille Transfusion Sanguine | Procede de preparation de solutions d'albumine purifiee |
| JPH0768137B2 (ja) * | 1989-06-15 | 1995-07-26 | 株式会社ミドリ十字 | アルブミン製剤及びその製法 |
| US5250662A (en) * | 1989-10-05 | 1993-10-05 | Alpha Therapeutic Corporation | Albumin purification |
| CA2022165C (en) * | 1989-10-05 | 1999-11-23 | Chong E. Chang | Albumin purification |
| FR2672604B1 (fr) * | 1991-02-07 | 1995-05-05 | Pasteur Merieux Serums Vacc | Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue. |
| KR930702381A (ko) * | 1991-07-12 | 1993-09-08 | 한스 발터 라벤 | 혈청 알부민의 정제방법 |
| US5849874A (en) * | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| FR2686620B1 (fr) * | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
| JPH07102147B2 (ja) * | 1992-03-16 | 1995-11-08 | 株式会社ミドリ十字 | ヒト血清アルブミンの着色抑制方法 |
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| AUPM388494A0 (en) * | 1994-02-16 | 1994-03-10 | Csl Limited | Process for removing endotoxins |
| JP3702474B2 (ja) | 1994-06-01 | 2005-10-05 | 三菱ウェルファーマ株式会社 | 血清アルブミン製剤の製造方法 |
| DE19538625C2 (de) * | 1995-10-17 | 1999-08-12 | Sartorius Gmbh | Verfahren zur Abtrennung von Albumin aus Serum durch Membranionenaustauschchromatographie |
| ES2103236B1 (es) * | 1996-01-30 | 1998-04-16 | Grifols Grupo Sa | Albumina humana terapeutica con baja capacidad para la fijacion de aluminio. |
| US5936003A (en) * | 1997-03-03 | 1999-08-10 | Dionex Corporation | Hydrolytically stable resins for use in anion-exchange chromatography |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| US6693173B2 (en) | 2000-12-26 | 2004-02-17 | Alpha Therapeutic Corporation | Method to remove citrate and aluminum from proteins |
| US7365173B2 (en) * | 2002-02-04 | 2008-04-29 | American National Red Cross | Method for the production of pure virally inactivated butyrylcholinesterase |
| AU2010215959A1 (en) | 2009-02-20 | 2011-08-04 | Ventria Bioscience | Cell culture media containing combinations of proteins |
| CN102816230B (zh) * | 2012-08-27 | 2014-02-12 | 同路生物制药股份有限公司 | 人血白蛋白的制备方法 |
| CN110878120B (zh) * | 2019-10-31 | 2023-06-13 | 华兰生物工程重庆有限公司 | 一种从组分ii上清液中回收白蛋白的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1042594B (de) * | 1955-09-02 | 1958-11-06 | Roehm & Haas Gmbh | Verfahren zur Reindarstellung von wasserloeslichen Eiweissstoffen |
| US3657116A (en) * | 1971-05-05 | 1972-04-18 | Wolfgang Haller | Process for the separation of blood components |
| US3959128A (en) * | 1974-12-27 | 1976-05-25 | Preventive Systems, Inc | Process for removing endotoxin from biological fluids |
-
1975
- 1975-10-09 SE SE7511295A patent/SE405549B/xx not_active IP Right Cessation
-
1976
- 1976-09-28 US US05/727,611 patent/US4086222A/en not_active Expired - Lifetime
- 1976-10-07 FR FR7630174A patent/FR2327256A1/fr active Granted
- 1976-10-08 JP JP51121170A patent/JPS5247915A/ja active Granted
- 1976-10-08 GB GB41995/76A patent/GB1554592A/en not_active Expired
- 1976-10-08 DE DE2645466A patent/DE2645466C2/de not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2742150A1 (de) * | 1976-09-20 | 1978-03-23 | Monsanto Co | Verfahren zur herstellung von serumalbumin |
Also Published As
| Publication number | Publication date |
|---|---|
| SE7511295L (sv) | 1977-04-10 |
| JPS5247915A (en) | 1977-04-16 |
| FR2327256A1 (fr) | 1977-05-06 |
| SE405549B (sv) | 1978-12-18 |
| JPS5632317B2 (enrdf_load_stackoverflow) | 1981-07-27 |
| DE2645466A1 (de) | 1977-04-21 |
| US4086222A (en) | 1978-04-25 |
| GB1554592A (en) | 1979-10-24 |
| FR2327256B1 (enrdf_load_stackoverflow) | 1978-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2645466C2 (de) | Verfahren zum Isolieren von Albumin aus Plasmaprodukten | |
| CH634334A5 (de) | Neues glycoprotein und verfahren zu dessen herstellung. | |
| DE2854381A1 (de) | Verfahren zur gewinnung des antihaemophilen faktors viii aus blut, blutplasma oder blutplasma-fraktionen | |
| DE69128088T2 (de) | Trennung der proteine und farbstoffe | |
| DE3039566A1 (de) | Verfahren zur reinigung von interferon | |
| DE2127159C2 (de) | IgG-Immunglobulinfraktion und ihre Herstellung | |
| DE3043409C2 (enrdf_load_stackoverflow) | ||
| DE2640387C3 (de) | Gewebespezifisches Protein und Verfahren zu dessen Herstellung | |
| DE69835957T2 (de) | Methoden zur isolation von proteinaseinhibitor proteinen von kartoffel knollen | |
| EP0033000B1 (de) | Neues Protein PP15, ein Verfahren zu seiner Herstellung sowie seine Verwendung | |
| DE2323981C3 (de) | Verfahren zur Isolierung des thrombinartig wirkenden Bestandteils aus dem Gift der Otter Agkistrodon rhodostoma | |
| DE2742150C2 (enrdf_load_stackoverflow) | ||
| DE69303941T2 (de) | Verfahren zur Herstellung von hochreinem Fibrinogen | |
| DE2259405C2 (de) | Verfahren zur Gewinnung von Orgotein aus roten Blutzellen | |
| DE69030414T2 (de) | Reinigung von Albumin | |
| DE2732587C2 (enrdf_load_stackoverflow) | ||
| DE2715748C3 (de) | Gereinigte aktive Verbindung des Plasminogen-Typs menschlichen Ursprungs und ihre Verwendung | |
| DE3044773C2 (enrdf_load_stackoverflow) | ||
| CH575433A5 (en) | Treatment of post-traumatic arthritis - with orgotein | |
| DE2428955A1 (de) | Verfahren zur extraktion von bestandteilen mit in vivo antikoagulierender wirkung aus schlangengiften und daraus erhaltene produkte | |
| DE2815853A1 (de) | Gereinigte urokinasepraeparate und verfahren zu ihrer herstellung | |
| DE69409390T2 (de) | Verfahren zur Extraktion und Reinigung von Alpha-1-Antitrypsin (alpha 1-pI) aus Cohnischer Fraktion IV-1 | |
| DE2635894A1 (de) | Verfahren zur herstellung eines antihaemophiles globulin a enthaltenden konzentrats | |
| DE2424118B2 (de) | Verfahren zur herstellung von hochreinem kallikrein | |
| DE2333884A1 (de) | Verfahren zur herstellung von gereinigtem albumin und das dabei erhaltene gereinigte albumin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8181 | Inventor (new situation) |
Free format text: LINDQUIST, LARS OLOF EDVARD BERGLOEF, JAN HAAKAN CURLING, JOHN MALCOLM, UPPSALA, SE |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |